Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.
Identifieur interne : 000F13 ( Main/Exploration ); précédent : 000F12; suivant : 000F14Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.
Auteurs : Nathan Touati [Belgique] ; Konstantinos Tryfonidis [Belgique] ; Franco Caramia [Australie] ; Hervé Bonnefoi [France] ; David Cameron [Royaume-Uni] ; Leen Slaets [Belgique] ; Belinda S. Parker [Australie] ; Sherene Loi [Australie]Source :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Agents de maintien de la densité osseuse (usage thérapeutique), Analyse de régression, Dénosumab (usage thérapeutique), Facteur-7 de régulation d'interféron (immunologie), Facteur-7 de régulation d'interféron (métabolisme), Femelle, Humains, Immunité innée (physiologie), Incidence, Infection (immunologie), Métastase tumorale (immunologie), Neutropénie fébrile (immunologie), Sujet âgé, Traitement médicamenteux adjuvant, Tumeurs du sein (anatomopathologie), Tumeurs du sein (immunologie), Tumeurs du sein (métabolisme), Tumeurs du sein (traitement médicamenteux), Tumeurs osseuses (secondaire), Tumeurs osseuses (épidémiologie), Études de suivi.
- MESH :
- anatomopathologie : Tumeurs du sein.
- immunologie : Facteur-7 de régulation d'interféron, Infection, Métastase tumorale, Neutropénie fébrile, Tumeurs du sein.
- métabolisme : Facteur-7 de régulation d'interféron, Tumeurs du sein.
- physiologie : Immunité innée.
- secondaire : Tumeurs osseuses.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Agents de maintien de la densité osseuse, Dénosumab.
- épidémiologie : Tumeurs osseuses.
- Adulte, Adulte d'âge moyen, Analyse de régression, Femelle, Humains, Incidence, Sujet âgé, Traitement médicamenteux adjuvant, Études de suivi.
English descriptors
- KwdEn :
- Adult, Aged, Bone Density Conservation Agents (therapeutic use), Bone Neoplasms (epidemiology), Bone Neoplasms (secondary), Breast Neoplasms (drug therapy), Breast Neoplasms (immunology), Breast Neoplasms (metabolism), Breast Neoplasms (pathology), Chemotherapy, Adjuvant, Denosumab (therapeutic use), Febrile Neutropenia (immunology), Female, Follow-Up Studies, Humans, Immunity, Innate (physiology), Incidence, Infection (immunology), Interferon Regulatory Factor-7 (immunology), Interferon Regulatory Factor-7 (metabolism), Middle Aged, Neoplasm Metastasis (immunology), Regression Analysis.
- MESH :
- chemical , immunology : Interferon Regulatory Factor-7.
- chemical , metabolism : Interferon Regulatory Factor-7.
- chemical , therapeutic use : Bone Density Conservation Agents, Denosumab.
- drug therapy : Breast Neoplasms.
- epidemiology : Bone Neoplasms.
- immunology : Breast Neoplasms, Febrile Neutropenia, Infection, Neoplasm Metastasis.
- metabolism : Breast Neoplasms.
- pathology : Breast Neoplasms.
- physiology : Immunity, Innate.
- secondary : Bone Neoplasms.
- Adult, Aged, Chemotherapy, Adjuvant, Female, Follow-Up Studies, Humans, Incidence, Middle Aged, Regression Analysis.
Abstract
Breast cancer cells which express an innate immune signature regulated by interferon regulatory factor 7 (IRF7) have reduced metastatic potential. Infections can induce interferon signalling and may activate an anti-tumour immune response. We investigated whether 'severe infection' can be a clinical surrogate of this phenomenon and/or the presence of high levels of the IRF7 signature at diagnosis before neo-adjuvant chemotherapy (NACT) is associated with a reduced distant relapse risk, specifically in bones.
DOI: 10.1016/j.ejca.2016.11.015
PubMed: 28027521
Affiliations:
- Australie, Belgique, France, Royaume-Uni
- Aquitaine, Nouvelle-Aquitaine, Victoria (État), Vienne (Autriche)
- Bordeaux, Melbourne, Vienne (Autriche)
- Université de Melbourne
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001095
- to stream PubMed, to step Curation: 001092
- to stream PubMed, to step Checkpoint: 001092
- to stream Ncbi, to step Merge: 004095
- to stream Ncbi, to step Curation: 004095
- to stream Ncbi, to step Checkpoint: 004095
- to stream Main, to step Merge: 000F08
- to stream Main, to step Curation: 000F13
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.</title><author><name sortKey="Touati, Nathan" sort="Touati, Nathan" uniqKey="Touati N" first="Nathan" last="Touati">Nathan Touati</name><affiliation wicri:level="3"><nlm:affiliation>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: nathan.touati@eortc.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels</wicri:regionArea><placeName><region type="land" nuts="2">Vienne (Autriche)</region><settlement type="city">Vienne (Autriche)</settlement></placeName></affiliation></author><author><name sortKey="Tryfonidis, Konstantinos" sort="Tryfonidis, Konstantinos" uniqKey="Tryfonidis K" first="Konstantinos" last="Tryfonidis">Konstantinos Tryfonidis</name><affiliation wicri:level="3"><nlm:affiliation>EORTC, Medical Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: Konstantinos.tryfonidis@eortc.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>EORTC, Medical Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels</wicri:regionArea><placeName><region type="land" nuts="2">Vienne (Autriche)</region><settlement type="city">Vienne (Autriche)</settlement></placeName></affiliation></author><author><name sortKey="Caramia, Franco" sort="Caramia, Franco" uniqKey="Caramia F" first="Franco" last="Caramia">Franco Caramia</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: Franco.Caramia@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Bonnefoi, Herve" sort="Bonnefoi, Herve" uniqKey="Bonnefoi H" first="Hervé" last="Bonnefoi">Hervé Bonnefoi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Institut Bergonié Unicancer, INSERM CIC1401, Bordeaux, France. Electronic address: H.Bonnefoi@bordeaux.unicancer.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Institut Bergonié Unicancer, INSERM CIC1401, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Cameron, David" sort="Cameron, David" uniqKey="Cameron D" first="David" last="Cameron">David Cameron</name><affiliation wicri:level="1"><nlm:affiliation>Western General Hospital, Edinburgh Cancer Centre, Crewe Road South, GB Edinburgh EH4 2XU, UK. Electronic address: D.Cameron@ed.ac.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Western General Hospital, Edinburgh Cancer Centre, Crewe Road South, GB Edinburgh EH4 2XU</wicri:regionArea><wicri:noRegion>GB Edinburgh EH4 2XU</wicri:noRegion></affiliation></author><author><name sortKey="Slaets, Leen" sort="Slaets, Leen" uniqKey="Slaets L" first="Leen" last="Slaets">Leen Slaets</name><affiliation wicri:level="3"><nlm:affiliation>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: leen.slaets@eortc.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels</wicri:regionArea><placeName><region type="land" nuts="2">Vienne (Autriche)</region><settlement type="city">Vienne (Autriche)</settlement></placeName></affiliation></author><author><name sortKey="Parker, Belinda S" sort="Parker, Belinda S" uniqKey="Parker B" first="Belinda S" last="Parker">Belinda S. Parker</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia. Electronic address: Belinda.Parker@Iatrobe.edu.uk.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: sherene.loi@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28027521</idno><idno type="pmid">28027521</idno><idno type="doi">10.1016/j.ejca.2016.11.015</idno><idno type="wicri:Area/PubMed/Corpus">001095</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001095</idno><idno type="wicri:Area/PubMed/Curation">001092</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001092</idno><idno type="wicri:Area/PubMed/Checkpoint">001092</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001092</idno><idno type="wicri:Area/Ncbi/Merge">004095</idno><idno type="wicri:Area/Ncbi/Curation">004095</idno><idno type="wicri:Area/Ncbi/Checkpoint">004095</idno><idno type="wicri:Area/Main/Merge">000F08</idno><idno type="wicri:Area/Main/Curation">000F13</idno><idno type="wicri:Area/Main/Exploration">000F13</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.</title><author><name sortKey="Touati, Nathan" sort="Touati, Nathan" uniqKey="Touati N" first="Nathan" last="Touati">Nathan Touati</name><affiliation wicri:level="3"><nlm:affiliation>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: nathan.touati@eortc.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels</wicri:regionArea><placeName><region type="land" nuts="2">Vienne (Autriche)</region><settlement type="city">Vienne (Autriche)</settlement></placeName></affiliation></author><author><name sortKey="Tryfonidis, Konstantinos" sort="Tryfonidis, Konstantinos" uniqKey="Tryfonidis K" first="Konstantinos" last="Tryfonidis">Konstantinos Tryfonidis</name><affiliation wicri:level="3"><nlm:affiliation>EORTC, Medical Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: Konstantinos.tryfonidis@eortc.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>EORTC, Medical Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels</wicri:regionArea><placeName><region type="land" nuts="2">Vienne (Autriche)</region><settlement type="city">Vienne (Autriche)</settlement></placeName></affiliation></author><author><name sortKey="Caramia, Franco" sort="Caramia, Franco" uniqKey="Caramia F" first="Franco" last="Caramia">Franco Caramia</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: Franco.Caramia@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Bonnefoi, Herve" sort="Bonnefoi, Herve" uniqKey="Bonnefoi H" first="Hervé" last="Bonnefoi">Hervé Bonnefoi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Institut Bergonié Unicancer, INSERM CIC1401, Bordeaux, France. Electronic address: H.Bonnefoi@bordeaux.unicancer.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Institut Bergonié Unicancer, INSERM CIC1401, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Cameron, David" sort="Cameron, David" uniqKey="Cameron D" first="David" last="Cameron">David Cameron</name><affiliation wicri:level="1"><nlm:affiliation>Western General Hospital, Edinburgh Cancer Centre, Crewe Road South, GB Edinburgh EH4 2XU, UK. Electronic address: D.Cameron@ed.ac.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Western General Hospital, Edinburgh Cancer Centre, Crewe Road South, GB Edinburgh EH4 2XU</wicri:regionArea><wicri:noRegion>GB Edinburgh EH4 2XU</wicri:noRegion></affiliation></author><author><name sortKey="Slaets, Leen" sort="Slaets, Leen" uniqKey="Slaets L" first="Leen" last="Slaets">Leen Slaets</name><affiliation wicri:level="3"><nlm:affiliation>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels, Belgium. Electronic address: leen.slaets@eortc.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>EORTC, Statistics Department, Avenue Emmanuel Mounier 83b11, 1200 Brussels</wicri:regionArea><placeName><region type="land" nuts="2">Vienne (Autriche)</region><settlement type="city">Vienne (Autriche)</settlement></placeName></affiliation></author><author><name sortKey="Parker, Belinda S" sort="Parker, Belinda S" uniqKey="Parker B" first="Belinda S" last="Parker">Belinda S. Parker</name><affiliation wicri:level="3"><nlm:affiliation>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia. Electronic address: Belinda.Parker@Iatrobe.edu.uk.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: sherene.loi@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Bone Density Conservation Agents (therapeutic use)</term><term>Bone Neoplasms (epidemiology)</term><term>Bone Neoplasms (secondary)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (immunology)</term><term>Breast Neoplasms (metabolism)</term><term>Breast Neoplasms (pathology)</term><term>Chemotherapy, Adjuvant</term><term>Denosumab (therapeutic use)</term><term>Febrile Neutropenia (immunology)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Immunity, Innate (physiology)</term><term>Incidence</term><term>Infection (immunology)</term><term>Interferon Regulatory Factor-7 (immunology)</term><term>Interferon Regulatory Factor-7 (metabolism)</term><term>Middle Aged</term><term>Neoplasm Metastasis (immunology)</term><term>Regression Analysis</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Agents de maintien de la densité osseuse (usage thérapeutique)</term><term>Analyse de régression</term><term>Dénosumab (usage thérapeutique)</term><term>Facteur-7 de régulation d'interféron (immunologie)</term><term>Facteur-7 de régulation d'interféron (métabolisme)</term><term>Femelle</term><term>Humains</term><term>Immunité innée (physiologie)</term><term>Incidence</term><term>Infection (immunologie)</term><term>Métastase tumorale (immunologie)</term><term>Neutropénie fébrile (immunologie)</term><term>Sujet âgé</term><term>Traitement médicamenteux adjuvant</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (immunologie)</term><term>Tumeurs du sein (métabolisme)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Tumeurs osseuses (secondaire)</term><term>Tumeurs osseuses (épidémiologie)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Interferon Regulatory Factor-7</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Interferon Regulatory Factor-7</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bone Density Conservation Agents</term><term>Denosumab</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Facteur-7 de régulation d'interféron</term><term>Infection</term><term>Métastase tumorale</term><term>Neutropénie fébrile</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Breast Neoplasms</term><term>Febrile Neutropenia</term><term>Infection</term><term>Neoplasm Metastasis</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Facteur-7 de régulation d'interféron</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Immunité innée</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Immunity, Innate</term></keywords><keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Tumeurs osseuses</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term><term>Dénosumab</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Tumeurs osseuses</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Chemotherapy, Adjuvant</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Middle Aged</term><term>Regression Analysis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de régression</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Sujet âgé</term><term>Traitement médicamenteux adjuvant</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Breast cancer cells which express an innate immune signature regulated by interferon regulatory factor 7 (IRF7) have reduced metastatic potential. Infections can induce interferon signalling and may activate an anti-tumour immune response. We investigated whether 'severe infection' can be a clinical surrogate of this phenomenon and/or the presence of high levels of the IRF7 signature at diagnosis before neo-adjuvant chemotherapy (NACT) is associated with a reduced distant relapse risk, specifically in bones.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>France</li><li>Royaume-Uni</li></country><region><li>Aquitaine</li><li>Nouvelle-Aquitaine</li><li>Victoria (État)</li><li>Vienne (Autriche)</li></region><settlement><li>Bordeaux</li><li>Melbourne</li><li>Vienne (Autriche)</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><country name="Belgique"><region name="Vienne (Autriche)"><name sortKey="Touati, Nathan" sort="Touati, Nathan" uniqKey="Touati N" first="Nathan" last="Touati">Nathan Touati</name></region><name sortKey="Slaets, Leen" sort="Slaets, Leen" uniqKey="Slaets L" first="Leen" last="Slaets">Leen Slaets</name><name sortKey="Tryfonidis, Konstantinos" sort="Tryfonidis, Konstantinos" uniqKey="Tryfonidis K" first="Konstantinos" last="Tryfonidis">Konstantinos Tryfonidis</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Caramia, Franco" sort="Caramia, Franco" uniqKey="Caramia F" first="Franco" last="Caramia">Franco Caramia</name></region><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><name sortKey="Parker, Belinda S" sort="Parker, Belinda S" uniqKey="Parker B" first="Belinda S" last="Parker">Belinda S. Parker</name></country><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Bonnefoi, Herve" sort="Bonnefoi, Herve" uniqKey="Bonnefoi H" first="Hervé" last="Bonnefoi">Hervé Bonnefoi</name></region></country><country name="Royaume-Uni"><noRegion><name sortKey="Cameron, David" sort="Cameron, David" uniqKey="Cameron D" first="David" last="Cameron">David Cameron</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28027521
|texte= Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28027521" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |